Get the Stockscreener App
1.41
0.71%
0.01
After Hours:
1.38
-0.03
-2.13%
Context Therapeutics Inc stock is traded at $1.41, with a volume of 425.75K.
It is up +0.71% in the last 24 hours and up +68.86% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.40
Open:
$1.44
24h Volume:
425.75K
Relative Volume:
1.90
Market Cap:
$126.48M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.5495
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+16.53%
1M Performance:
+68.86%
6M Performance:
+80.75%
1Y Performance:
-28.06%
1-Day Range:
$1.3702
$1.515
1-Week Range:
$1.085
$1.55
52-Week Range:
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.41 | 125.59M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
How to use Fibonacci retracement on Context Therapeutics Inc.2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Is Context Therapeutics Inc. stock positioned well for digital economyMarket Rally & Verified Short-Term Plans - newser.com
Momentum divergence signals in Context Therapeutics Inc. chart2025 Big Picture & AI Powered Trade Plan Recommendations - newser.com
Can a trend reversal in Context Therapeutics Inc. lead to recovery2025 Retail Activity & Real-Time Price Movement Reports - newser.com
Context Therapeutics to Present New Data on Two Bispecific T Cell Engagers at SITC 2025 - MyChesCo
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
What drives Context Therapeutics Inc stock priceCandlestick Trading Patterns & Unlock Patterns Humans Can’t See - earlytimes.in
Is Context Therapeutics Inc. stock ready for a breakoutNew Guidance & Low Risk Entry Point Tips - newser.com
Will Context Therapeutics Inc. continue its uptrendLayoff News & AI Based Buy and Sell Signals - newser.com
Historical volatility pattern of Context Therapeutics Inc. visualizedQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Real time social sentiment graph for Context Therapeutics Inc.Portfolio Update Summary & Free Weekly Watchlist of Top Performers - newser.com
Live market analysis of Context Therapeutics Inc.July 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
Context Therapeutics Inc. stock momentum explained2025 Dividend Review & Risk Controlled Daily Trade Plans - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Context Therapeutics (NASDAQ:CNTX) - MarketBeat
How Context Therapeutics Inc. stock trades before earningsQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Is a relief rally coming for Context Therapeutics Inc. holdersIndex Update & AI Driven Stock Reports - newser.com
Is Context Therapeutics Inc. showing signs of accumulationEarnings Summary Report & Stepwise Trade Signal Implementation - newser.com
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Yahoo Finance
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.20 Consensus PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Hire - MSN
Will Context Therapeutics Inc. see short term momentumJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
Context Therapeutics Announces Poster Presentations at the - GlobeNewswire
Context Therapeutics Inc. to Present Trial Progress and Preclinical Data at SITC 2025 Annual Meeting - Quiver Quantitative
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of ... - Caledonian Record
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Is it too late to sell Context Therapeutics Inc.2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Context Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - MarketScreener
Developing predictive dashboards with Context Therapeutics Inc. dataJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics announces inducement grant under Nasdaq listing rule - MarketScreener
GlobeNewswire by Notified - The Manila Times
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
30,000-Share Option: Context Therapeutics Grants New Hire Award at $0.97 Exercise Price, 10-year Term - Stock Titan
Context Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st
Is Context Therapeutics Inc. stock in correction or buying zoneWeekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Cantor Fitzgerald Initiates Coverage of Context Therapeutics (CNTX) with Overweight Recommendation - Nasdaq
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):